Rabies

9
Pipeline Programs
5
Companies
12
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
4
0
1
0
2
2
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Vaccine
480%
RNA Therapeutic
120%
+ 7 programs with unclassified modality

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Novartis
NovartisBASEL, Switzerland
4 programs
1
2
1
Purified Chick Embryo Cell Inactivated Rabies VaccinePhase 4Vaccine1 trial
Abbreviated Zagreb 2-1-1 schedulePhase 31 trial
ZagrebPhase 31 trial
Three 1 mL doses of Rabies vaccine and two JE vaccinePhase 2Vaccine1 trial
Active Trials
NCT00694460Completed200Est. Sep 2004
NCT00825305Completed825Est. Jan 2009
NCT01680016Completed644Est. Jan 2013
+1 more trials
Sanofi
SanofiPARIS, France
1 program
1
Purified Verocell Rabies VaccinePhase 4Vaccine1 trial
Active Trials
NCT00260351Completed405Est. Oct 2008
Grifols
GrifolsNEW YORK, NY
3 programs
1
RIG-CPhase 11 trial
Human rabies immune globulin 300 IU/mLN/A1 trial
Rabies PEP quality improvement bundleN/A1 trial
Active Trials
NCT05382650TerminatedEst. Oct 2025
NCT04213950CompletedEst. Dec 2020
NCT02139657CompletedEst. May 2014
C
CureVacGermany - Tübingen
3 programs
3
CV7201 mRNAPhase 1RNA Therapeutic1 trial
CV8102Phase 11 trial
Rabipur®Phase 11 trial
Active Trials
NCT02241135CompletedEst. Feb 2018
NCT02238756CompletedEst. Nov 2016
NCT03713086CompletedEst. Nov 2021
CSL Behring
CSL BehringIL - Bradley
1 program
Rabies VaccineN/AVaccine1 trial
Active Trials
NCT01063140Completed491Est. May 2010

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
NovartisPurified Chick Embryo Cell Inactivated Rabies Vaccine
SanofiPurified Verocell Rabies Vaccine
NovartisZagreb
NovartisAbbreviated Zagreb 2-1-1 schedule
NovartisThree 1 mL doses of Rabies vaccine and two JE vaccine
CureVacRabipur®
CureVacCV8102
GrifolsRIG-C
CureVacCV7201 mRNA
GrifolsHuman rabies immune globulin 300 IU/mL
GrifolsRabies PEP quality improvement bundle
CSL BehringRabies Vaccine

Clinical Trials (12)

Total enrollment: 2,815 patients across 12 trials

NCT01365494NovartisPurified Chick Embryo Cell Inactivated Rabies Vaccine

Immunogenicity and Safety of Rabies Vaccine, Administered With Two Different Simulated Post Exposure Schedules

Start: Jul 2011Est. completion: Nov 2011250 patients
Phase 4Completed
NCT00260351SanofiPurified Verocell Rabies Vaccine

Immunogenicity and Safety of Verorab™ in Indian Population

Start: Dec 2004Est. completion: Oct 2008405 patients
Phase 4Completed
NCT01680016NovartisZagreb

A Randomized, Open-label Study Comparing Two Different Rabies Vaccine Schedules in Chinese Children and Older Adults

Start: Sep 2012Est. completion: Jan 2013644 patients
Phase 3Completed
NCT00825305NovartisAbbreviated Zagreb 2-1-1 schedule

Safety and Immunogenicity (Non-inferiority) of a Purified Chick Embryo Cell Vaccine Vaccine Administered in Two Different Schedules (Conventional Versus Abbreviated Schedule)

Start: Nov 2008Est. completion: Jan 2009825 patients
Phase 3Completed
NCT00694460NovartisThree 1 mL doses of Rabies vaccine and two JE vaccine

Evalution of Immunogenicity, Safety and Booster Response of a Rabies Vaccine Administered Concomitantly With Japanese Encephalitis Vaccine in Toddlers

Start: Aug 2002Est. completion: Sep 2004200 patients
Phase 2Completed
NCT03713086CureVacRabipur®

A Study to Assess the Safety, Reactogenicity and Immune Response of CureVac's Candidate Rabies mRNA Vaccine in Healthy Adults

Start: Oct 2018Est. completion: Nov 2021
Phase 1Completed
NCT02238756CureVacCV8102

Safety and Tolerability of CV8102 Alone and in Combination With a Rabies Virus Vaccine in Healthy Adults

Start: Sep 2014Est. completion: Nov 2016
Phase 1Completed
NCT02139657GrifolsRIG-C

An Open-label, Single-Arm Study to Evaluate the Safety and Rabies Virus Antibody Titers of Intramuscularly Administered Rabies Immune Globulin (Human)

Start: Mar 2014Est. completion: May 2014
Phase 1Completed
NCT02241135CureVacCV7201 mRNA

RNActive® Rabies Vaccine (CV7201) in Healthy Adults

Start: Oct 2013Est. completion: Feb 2018
Phase 1Completed
NCT05382650GrifolsHuman rabies immune globulin 300 IU/mL

Survey of Human Rabies Immune Globulin Safety in Children

Start: Feb 2023Est. completion: Oct 2025
N/ATerminated
NCT04213950GrifolsRabies PEP quality improvement bundle

Improving Adherence to Rabies PEP Guideline Recommendations

Start: Dec 2019Est. completion: Dec 2020
N/ACompleted
NCT01063140CSL BehringRabies Vaccine

Rabies Immune Plasma Booster Study

Start: Jan 2009Est. completion: May 2010491 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
5 companies competing in this space